Back to Authors

Kumar, Shaji

https://orcid.org/0000-0001-5392-9284

A5026574827 | I1330342723

Mayo Clinic

Citations 1268

Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8062-8062

10.1200/jco.2016.34.15_suppl.8062

Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8058-8058

10.1200/jco.2016.34.15_suppl.8058

Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8053-8053

10.1200/jco.2016.34.15_suppl.8053

Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8032-8032

10.1200/jco.2016.34.15_suppl.8032

Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8016-8016

10.1200/jco.2016.34.15_suppl.8016

Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8015-8015

10.1200/jco.2016.34.15_suppl.8015

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011

10.1200/jco.2016.34.15_suppl.8011

A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8008-8008

10.1200/jco.2016.34.15_suppl.8008

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8005-8005

10.1200/jco.2016.34.15_suppl.8005

Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7552-7552

10.1200/jco.2016.34.15_suppl.7552